Efficacy and safety of NS2359 in adults with attention deficit hyperactivity disorder. A randomised, double-blind, placebo-controlled study
Latest Information Update: 08 May 2007
At a glance
- Drugs NS 2359 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors NeuroSearch
- 08 May 2007 New trial record.
- 08 Nov 2004 Primary endpoint 'ADHD Symptom-score' was not met, according to a NeuroSearch media release.